Autoimmune Liver Disease
Conditions
Keywords
Autoimmune liver disease, glycyrrhizic acid, liver function
Brief summary
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, were enrolled. Clinical follow-up data including demographics, hematuria, and liver and kidney were collected. Functional, electrolyte blood glucose, PTA, erythrocyte sedimentation rate, serum AFP and other clinical biochemical indicators and autoantibodies, special proteins and liver imaging (liver ultrasound) examination. The clinical effect of glycyrrhizic acid preparation for the treatment of autoimmune liver disease for 144 weeks and the safety during treatment were analyzed.
Detailed description
This study was a retrospective clinical observation cohort study. All patients with autoimmune liver disease treated with glycyrrhizic acid preparations in the Department of Liver Diseases, Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, were enrolled. Clinical follow-up data including demographics, hematuria, and liver and kidney were collected. Functional, electrolyte blood glucose, PTA, erythrocyte sedimentation rate, serum AFP and other clinical biochemical indicators and autoantibodies, special proteins and liver imaging (liver ultrasound) examination. The clinical effect of glycyrrhizic acid preparation for the treatment of autoimmune liver disease for 144 weeks and the safety during treatment were analyzed.
Interventions
DRUGGlycyrrhizic acid preparation
To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
Sponsors
Beijing Ditan Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\) Patients with autoimmune liver disease: All enrolled autoimmune liver diseases meet the diagnostic criteria of China's Consensus on Diagnosis and Treatment of Autoimmune Liver Disease (2015); * 2\) no hormones and / or immunosuppressants and other liver protection drugs; * 3\) Sign the written informed consent form.
Exclusion criteria
* 1\) Combine other hepatitis virus (HCV, HDV) infections; * 2\) viral liver disease; * 3\) HIV infection; * 4\) long-term alcohol abuse and / or other liver damage drugs; * 5\) mental illness; * 6\) Evidence of liver tumors (liver cancer or AFP \> 100 ng/ml); * 7\) decompensated cirrhosis; * 8\) Serious diseases such as heart, brain, lung, kidney, etc. can not participate in long-term follow-up; * 9\) There are hormones and / or immunosuppressants and other liver protection drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The ratio of sustained biochemical responses | at 96 weeks and 144 weeks after treatment | The ratio of sustained biochemical responses at 96 weeks and 144 weeks after treatment with glycyrrhizic acid preparation in patients with autoimmune liver disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of decompensated liver cirrhosis and liver cancer and its complications | at 96 and 144 weeks after treatment | The incidence of decompensated liver cirrhosis and liver cancer and its complications at 96 and 144 weeks after treatment with glycyrrhizic acid in patients with autoimmune liver disease |
Countries
China
Outcome results
None listed